fbpx

Biological disease-modifying antirheumatic drugs (bDMARDS)

PSA has joined NPS MedicineWise and seven other organisations representing pharmacists, specialists, consumers and research experts to form the Targeted Therapies Alliance. The Alliance provides stewardship and direction about the safe and wise use of biological disease-modifying antirheumatic drugs (bDMARDs) and other specialised medicines.

Screening for cardiovascular disease risk in people living with HIV

The Pharmaceutical Society of Australia has developed a Screening for cardiovascular disease risk in people living with HIV checklist that can be used to help you screen for risk factors for CVD in your patients living with HIV and guide you to educate and refer those at increased risk to see their doctor for a comprehensive clinical assessment.

UTI Pharmacy Pilot – QLD

Urinary Tract Infection Pharmacy Pilot – Queensland:

Information for consumers

Women in Queensland now have access to immediate advice and treatment, including the supply of antibiotics when appropriate, for uncomplicated Urinary Tract Infections (UTI) through their local participating community pharmacy. 

 

The aim of this pilot is to improve access to healthcare for women, with one in two women experiencing a UTI in their lifetime. 

1. Who is eligible?

Non-pregnant women, aged 18-65 who are deemed to have an uncomplicated UTI are eligible to participate in the Pilot.

 

Men will not be eligible to be treated as part of the pilot as symptoms are not reflective of an uncomplicated UTI. 

    2. Find a participating pharmacy

3. When should I see my doctor?

If through the screening process you are deemed to not have an uncomplicated UTI, your treatment options may include a referral to a GP for further investigation.

4. FAQs

A UTI is an infection of the urinary system, which consists of the kidneys, ureters, bladder and urethra. It’s more common than you might think – 1 in 2 women may experience a UTI in their lifetime.1

 

When an infection affects the lower urinary tract (urethra or bladder), it may be called urethritis, or cystitis if it affects the bladder. When it affects the upper urinary tract (ureters or kidneys) it is called ureteritis, or pyelonephritis if it affects the kidneys.2

UTI are not serious for most women, but symptoms can range from mild to severe. For some people, a UTI can have serious complications, such as kidney damage, kidney failure, or sepsis (blood poisoning)3. It is important that you discuss your signs and symptoms with a healthcare professional to ensure you seek the correct medical advice and treatment.  Your community pharmacist can assist.

No, a UTI is not a sexually transmitted infection, but sometimes the symptoms can be similar. Your community pharmacist can discuss your symptoms and provide you with appropriate recommendations and advice.

This Pilot, giving women in Queensland access to immediate advice and treatment for uncomplicated UTIs through their local community pharmacy and participating pharmacist, has been developed in response to recommendations from the Parliamentary inquiry into the establishment of a pharmacy council and transfer of pharmacy ownership in Queensland.

 

Similar models of care for the management of uncomplicated UTIs by community pharmacists have been successfully implemented in the United Kingdom, Canada and New Zealand. 

No, you will not need to give a urine sample as part of this community pharmacy service.  Women who aren’t pregnant can be treated by community pharmacists for uncomplicated UTIs by evaluating their signs and symptoms. If, through the consultation process, your community pharmacist determines any complicating factors or determines that urine culture and testing is required, they will refer you to a general practitioner.

Symptoms of an uncomplicated UTI should respond to appropriate antibiotic therapy within 48 hours of commencing treatment. Dysuria (burning and stinging when urinating) usually improves within a few hours.

This service is being piloted in participating pharmacies in Queensland only.  All participating pharmacists are required to undertake mandatory training prior to administering the service.

 

Find a participating pharmacy above.

 

6. Information for Health Professionals

Urinary Tract Infection Pharmacy Pilot – Queensland (UTIPP-Q): The Facts

 

  1. Following on from Recommendation Two in the 2018 Parliamentary Inquiry into Community Pharmacy, the Department of Health has engaged the Queensland University of Technology (QUT) to develop, implement and evaluate a state-wide pilot of the management of urinary tract infections (UTIs) by community pharmacists.
  2. The service may be accessed by non-pregnant women, aged 18-65 who are deemed to have an uncomplicated urinary tract infection. Men will not be eligible to be treated as part of the pilot as symptoms are not reflective of an uncomplicated urinary tract infection.
  3. Participating pharmacists have undergone additional mandatory training to assess, diagnose and offer appropriate treatment to patients as part of the pilot. The approved online CPD training is available through both the Guild and PSA Learning and Development platform.
  4. Treatment options may include a supply of antibiotics (if appropriate). If, through the screening process, the patient is deemed to not have an uncomplicated urinary tract infection, their treatment options may include a referral to a GP for further investigation, as covered in the PSA Guidance for provision of antibiotics for acute uncomplicated cystitis in females (the practice standard).
  5. Models of care for the management of uncomplicated urinary tract infections by community pharmacists have been successfully implemented in the United Kingdom, Canada and New Zealand.
  6. Community pharmacy is easily accessible. In capital cities, 97% of consumers are no further than 2.5km from a community pharmacy. In regional areas, 65% of people are within 2.5 km of a pharmacy.
  7. Community pharmacies are the most frequently accessed and most accessible health destination, with over 456 million individual patient visits annually and the vast majority of pharmacies open after-hours, including weekends.
  8. Pharmacists are one of the most trusted professions. Public opinion surveys have shown that 84% of adults trust the advice they receive from pharmacists.
  9. Community pharmacists are accessible and understand this target demographic. At 30 September 2019, there were 32,035 registered pharmacists in Australia. 62.8% of pharmacists are women; and over 60% are under 40 years of age.

Digital Health Guidelines For Pharmacists

About the guidelines

Purpose

The Digital Health Guidelines for Pharmacists describe the professional obligations of pharmacists when interacting with digital health systems in performing their professional clinical roles. These guidelines provide guidance on expected professional practice when using digital health systems, so that pharmacists can provide optimal patient outcomes, while meeting legal and ethical obligations relating to data access and stewardship. The guidelines should be used as a tool to support practice and professional decision making, and ensure that patients’ needs, beliefs and preferences are met. They can be used as an educational resource to inform quality assurance processes, and provide support when resolving legal disputes and ethical dilemmas.

Scope

The Digital Health Guidelines for Pharmacists are applicable to all settings in which pharmacists practise and interact with digital health, including settings where the pharmacist does not dispense medicines.

 

Guidelines produced by the Pharmaceutical Society of Australia (PSA) are not definitive statements of correct procedure but represent agreement by experts in the field. The guidelines do not set a prescribed course of action or a mandatory standard to which pharmacists must adhere.

 

The guidelines do not provide a technical guide on how to operate digital health systems; rather, they provide guidance on the minimum professional and ethical behaviour for pharmacists when using digital health systems in the delivery of health services.

Acknowledgements

Development of the Digital Health Guidelines for Pharmacists has been supported by the Australian Digital Health Agency. This document supersedes the My Health Record Guidelines for Pharmacists (2019), and incorporates much of this previous version. The work to update the guidelines included review by experts, stakeholder feedback, and the consensus of organisations and individuals involved. The Pharmaceutical Society of Australia thanks all those involved in the review process and, in particular, gratefully acknowledges the contribution of the following individuals and organisations.

Broad hierarchy of guidance and regulation of pharmacy practice v2

Pharmacists are expected to exercise professional judgement when adapting the guidance provided in these guidelines to specific circumstances. The guidelines sit within a broader hierarchy of guidance underpinning and supporting the practice of pharmacists working with digital health systems (see Figure 1).

 

It is important to review these guidelines in conjunction with the current versions of the:

  • Pharmacy Board of Australia Code of Conduct for Pharmacists

  • National Competency Standards Framework for Pharmacists in Australia

  • PSA Code of Ethics for Pharmacists

    • PSA Dispensing Practice Guidelines

    • PSA Professional Practice Standards

    • Australian Commission on Safety and Quality in Health Care National Guidelines for On-Screen Display of Medicines Information (2017)

    • Australian Commission on Safety and Quality in Health Care National Guidelines for On-Screen Presentation of Discharge Summaries (2017)

Guideline Sections

Note: Refresh your page is you have any difficulty opening the Guideline Section

7CPA Resources

The 7th Community Pharmacy Agreement, which commenced on 1 July 2020, provides certainty, stability and flexibility for the pharmacy profession for the next five years.

S3 guidance documents

S3 guidance documents provide details of the recommended procedure for pharmacists to follow when supplying Pharmacist Only medicines. Following a systematic process helps pharmacists to fulfil their professional obligations

Prescription Medication Safety

As the custodians of medication safety, promoting the judicious, quality and safe use of prescription medications is key to the pharmacist’s role. This interactive, two-part program will delve into the importance of prescription medication safety, the societal impact of the misuse of medicines, and the impact that medications and substances can have on fitness to drive. Proudly funded by NSW Government.

 

Click Here for more information

HIV Resources

HIV treatment has evolved rapidly over the past 30 years since the discovery of HIV. Since the development of zidovudine (AZT) in 1986, a large number of antiretroviral (ARV) classes have been developed, all of which aim to interrupt the HIV replication cycle at different stages. Taken in combinations of three of more medicines, treatment with ARVs can be complex, especially in instances where co-morbidities impact on treatment choice. Being confident with providing HIV ARVs for treatment will lead to a better patient experience, with these resources designed to aid in supporting the delivery of high-quality HIV treatment services within the pharmacy setting.

Advancing Practice

This resource hub provides you with a suite of resources to support you in advancing your practice including support for formal recognition and credentialing as a, Stage I Advancing Practice Pharmacist, Stage II Advancing Practice Pharmacist and Advanced Practice Pharmacist.

Immunisation Resources

The PSA immunisation resource hub provides members with a suite of education and resources to support your practice as an immuniser. We will also keep you updated on the work PSA is doing to support members and advocate for pharmacists to expand their role as immunisers.